Transaction #33435 · Form 4 · 0001366074-26-000006
Inhibrx Biosciences, Inc. · Purchase · Common Stock
Inhibrx Biosciences, Inc. · Transacted October 14, 2026 · Filed October 14, 2026
What does this filing report?
An SEC Form 4 filing for Inhibrx Biosciences, Inc. records a purchase involving Common Stock on October 14, 2026. The reported quantity was 2,449. The filing date is October 14, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Inhibrx Biosciences, Inc.
- Company CIK
- 0002007919
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 2,449
- Reported price
- 84.0707 · See footnotes
- Reference value
- 205,889.1443
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 167,449
- Ownership description
- By Lappe Descendants' Trust
- SEC acceptance time
- Oct 14, 2026, 6:58 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Lappe Mark ↗
Chief Executive Officer · Director
CIK 0001366074
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The shares were purchased in multiple transactions at prices ranging from $83.61 to $84.59 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F2
- These securities are directly owned by the Lappe Family Trust. Mark P. Lappe is a trustee of the Lappe Family Trust and, in such capacity, may be deemed to indirectly beneficially own the securities owned by the Lappe Family Trust.
- F3
- The shares were purchased in multiple transactions at prices ranging from $84.65 to $85.62 inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- F4
- These securities are directly owned by a trust, for the benefit of the reporting person's immediate family. Mark P. Lappe, as an immediate family member of the beneficiaries of the trust, may be deemed to indirectly beneficially own the securities owned by the trust.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.